biologic

Anavip

Crotalidae Immune F(ab')2 (Equine)

Loss of exclusivityMay 2027projected — 12-year biologic exclusivity estimate
CompanyRare Disease Therapeutics, Inc. (RDT)

Drug detail

Brand nameAnavip
Active ingredientCrotalidae Immune F(ab')2 (Equine)
StrengthMINIMUM 780 BOTHROPS ASPER, 790 C.SIMUS, 244 C.ADAMANTEUS, 147 C.ATROX, 185 C.SCUTULATUS, 28 AGKISTRODON CONTORTRIX, 61 A.PISCIVORUS LD50 NEUTRALIZING UNITS/VIAL
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalMay 2015
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Anavip patent cliff — loss of exclusivity May 2027 | CliffBio